How many investments has Forbion made?

Forbion has 121 tracked investments, 6 of which have exited, including 23 dated in the last 24 months.

What stage does Forbion invest at?

Forbion invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

Where is Forbion located?

Forbion is headquartered in Naarden, NL.

Does Forbion lead rounds?

Forbion has led 10 of the 25 rounds where its role is on record.

Who does Forbion co-invest with?

Forbion most often shares deals with BioGeneration Ventures, BioMedPartners, DeepTech & Climate Fonds, among 13 tracked co-investors.

Forbion

Venture capitaloperating company · company profile

Naarden · Pre-Seed–Late Stage · 25 people tracked

Also known as FCPM III SERVICES B.V. · FORBION NORTH AMERICA LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Forbion

Paths you didn't know you had: your email and LinkedIn already hold routes to the Forbion team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

Forbion invests in biotech and sustainable innovation across two main areas: human health and planetary health. Its human health strategies span early-stage company formation (via a joint venture with BioGeneration Ventures), pre-clinical and early clinical Ventures, and later clinical-stage Growth investing that includes private growth capital, crossovers, and public market transactions. Its BioEconomy strategy backs companies using biotechnology to clean and feed the planet across food, agriculture, materials, and environmental technologies at Series A and beyond. The firm integrates ESG principles into its investments, emphasizing patient impact, societal benefit, and sustainability.

Invests inAgTech Biotech Cleantech Climate Tech FoodTech Healthtech Impact & Social Good Medical Devices New Materials Amsterdam Europe Germany Global Netherlands North America United States

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Pre-Seed–Late Stage

Naarden, NL

Instruments

Equity

Founded

1999

Last 12 months

15 investments

AUM

$5.4B

VC funds

Tracked investments

121

Unicorns

IPOs

Acquisitions

Team · 25 people

from the firm's website & public directories

Geert-Jan Mulder· Co-founding Managing Partner· Naarden, Netherlandsin

Geert-Jan Mulder is a co-founding Managing Partner at Forbion who has led investments across Europe and the US and works with portfolio company management teams on clinical development strategy and regulatory matters such as IND/NDA filings and orphan designations. Before Forbion, he was an Investment Director at ABN AMRO Capital Life Sciences from 2001, and earlier held roles in the pharmaceutical industry at Byk Gulden (now Takeda) as Clinical Research Manager and at Searle (now Pfizer) as Medical Adviser. He holds a Medical Degree from the University of Utrecht and completed two years of residency in Obstetrics and Gynaecology at the University Medical Centre of Utrecht.

Sander Slootweg· Co-founder & Managing Partner· Netherlandsin

Sander Slootweg is Managing Partner at Forbion, which he co-founded in 2006 after co-founding ABN AMRO Capital/Life Sciences in 2000. His earlier roles at ABN AMRO Bank included buy-out and growth equity investing, equity capital markets syndications, and financial institutions relationship management for Latin America. He holds degrees in Business and Financial Economics from the Free University of Amsterdam and in Business Administration from Nyenrode University, and focuses on life sciences investing.

Alexander Hoffmann· General Partner· Amsterdam Areain

Alexander Hoffmann is a General Partner at Forbion, where he set up and co-led the BioEconomy strategy. He previously was Managing Director at a family office joint-venture focused on early-stage bio-based climate startups, and began his venture career at M Ventures, the venture arm of Merck KGaA, covering Frontier Tech & Sustainability investments spanning digital healthcare and biotech. Earlier, he worked as an operator in tech startups and led Merck's digital strategy for its Africa operations from Nairobi, Kenya.

Dirk Kersten· Managing Partner· Amsterdam, Netherlandsin

Dirk Kersten is a Managing Partner at Forbion, which he joined in 2018, where he manages the Forbion Growth Opportunities Fund. Trained as a physicist, he previously served as a Partner at Gilde Healthcare Partners, leading its Boston office, and as a Managing Director at INKEF Capital overseeing healthcare investments. His work spans fund management, deal making, portfolio management, and exit strategies.

Dmitrij Hristodorov· General Partner· Munich, Germanyin

Dmitrij Hristodorov is a General Partner at Forbion, where his portfolio spans multiple stages, treatment modalities, and disease areas. He previously held R&D Ophthalmology and Business Development roles at Bayer Pharma. He earned a PhD from the University of Aachen (RWTH) in 2013 for immunology work conducted at the Fraunhofer Institute.

Jasper Bos· General Partner· Naarden, Netherlandsin

Jasper Bos is a General Partner at Forbion's Growth Fund. He previously served as Senior Vice President and Managing Director at M Ventures, Merck's venture arm, which he joined in 2009, where he led a team of investment professionals managing a €400 million fund across more than 50 biotech, life sciences tools, and tech companies. He holds a PhD in Pharmacy from the University of Groningen.

Jon Edwards· General Partner· Bostonin

Jon Edwards is a General Partner at Forbion who works on sourcing, evaluating, and structuring investments spanning company creation through early clinical development across therapeutic areas. He joined Forbion in 2025 and was previously a founding team member at Red Tree Venture Capital and Medicxi, with earlier roles at ClearView Healthcare Partners and Sepracor. He completed postdoctoral research at MIT and holds a PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.

Joy Faucher· General Partner· Netherlandsin

Joy Faucher is a General Partner at Forbion, which he joined in 2023 to establish and co-lead the firm's BioEconomy strategy. He previously invested in growth and early-stage companies at Lightrock and MVentures (Merck's corporate venture arm), and held operational roles at Formo and Eli Lilly's biotech commercial launch facility. He holds a Master's in Bioscience Enterprise from the University of Cambridge and a Bachelor's in Biochemical Engineering from University College London.

Marco Boorsma· General Partner· Amsterdam, Netherlandsin

Marco Boorsma is a General Partner at Forbion, which he joined in 2007. Before Forbion, he was Business Development Director at DSM Pharmaceutical Products and worked on manufacturing processes for biosimilars at Cytos Biotechnology. He focuses on biotechnology, operations, and business development, with an emphasis on founding and managing new companies as part of Forbion's build strategy, and holds an MSc in Molecular Biology from the University of Groningen and a PhD in Biotechnology from ETH Zürich.

Martien van Osch· Managing Partner· Boston, MAin 𝕏

Martien van Osch is Managing Partner, CFO and co-founder of Forbion, where he leads the firm's US office in Boston and sits on the Ventures and Growth investment committee. He represented Forbion in Asia from Singapore between 2018 and 2023 and previously led the firm's Fund I-III medical technology investments. Before co-founding Forbion in 2006, he spent six years as an Investment Director at ABN AMRO Capital Life Sciences and holds a degree in Econometrics from the Rijksuniversiteit Groningen.

Nanna Lüneborg· General Partner· Amsterdam Areain

General Partner at Forbion, holds a PhD and MBA.

Rogier Rooswinkel· General Partner· Naardenin

Rogier Rooswinkel is a General Partner at Forbion's Naarden office, which he joined in 2013, where he evaluates and structures new investment opportunities across disease areas with a focus on oncology. Before Forbion, he was a post-doctoral researcher at the Netherlands Cancer Institute (NKI) in the division of immunology, and during his studies he worked as an independent website designer and founded an IT company. He earned a PhD Cum Laude from the University of Amsterdam in 2013 for work at the NKI, and holds a Master's degree in Oncology from VU University Amsterdam.

Wouter Joustra· General Partner· Amsterdam, Netherlandsin

Wouter Joustra is a General Partner at Forbion, which he joined in 2019, where he works on deal origination, portfolio management, and divestment strategies with a focus on the firm's Growth Opportunities Funds targeting late-stage life sciences companies. He previously served as a Senior Trader and Executive Board member of the life sciences franchise at the investment bank Kempen. He holds an M.Sc. in Business Administration and a B.Sc. in International Business and Management, both from the University of Groningen.

Dirk Mertens· General Partner

Holger Reithinger· General Partner· Munich, Germanyin 𝕏

Jonathan McNeill· Partner

Regina Salvat· Partner

Antoine Boulanger Piette· Principal· Amsterdam, Netherlands

Audrey Cacaly· Principal· Netherlandsin

Philip Astley-Sparke· Venture Partner· Boston, Massachusettsin

Philip Astley-Sparke is Executive Chairman and co-founder of Replimune, a developer of oncolytic vaccines. He previously served as President and CEO of BioVex, which brought Imlygic to FDA approval in 2015 before its acquisition by Amgen in 2011, and as President of uniQure, where he established U.S. operations including a gene therapy manufacturing facility. Astley-Sparke holds a BSc in Cellular and Molecular Pathology from Bristol University, qualified as a Chartered Accountant, and has experience as a healthcare investment banker.

Carlo Incerti· Operating Partner· Jupiter, Florida, United States

Machteld Groeneveld· Legal Counsel and Compliance Officer· Amsterdam, North Holland, Netherlandsin

Machteld Groeneveld joined Forbion in June 2020 and is responsible for Legal, Risk and Compliance. She serves on the board of the Manager of the Forbion funds as Secretary, and is a member of the firm's Valuation Committee and Responsible Investing Committee. Before Forbion she held legal and strategic roles at multinational and publicly listed companies, focusing on European legal affairs, fund compliance, corporate strategy, and value creation through M&A. She holds an LLM from the University of Utrecht, a postgraduate degree in International Contracting from Grotius Academy, and an Executive MBA from RSM Erasmus University.

Robbert van de Griendt· Investor Relations· The Netherlandsin

Robbert leads fundraising and investor relations at BGV and heads Forbion's ESG and impact investing efforts. He previously founded Accretion Capital Partners and was a partner at Virage Capital and Neotech Capital, with over 20 years of experience across Asia, Europe, and North America, and holds a Business Economics degree from Erasmus University Rotterdam.

robbert@biogeneration.vc

Alice Vickers· Advisor· United Kingdomin 𝕏

Marc-Olivier Turgeon· Senior Associate· Amsterdam, Netherlandsin

What they invest in

from 78 of 121 portfolio companies

Biotech ×69Healthtech ×44Medical Devices ×35Digital Health ×13Deep Tech ×12AI & Machine Learning ×11SaaS ×3Cleantech ×2

HQs:United States×22United Kingdom×7Germany×4Netherlands×4Switzerland×3Colombia×1

Investments · 121 tracked

founders shown can be your intro path

By year:2026 · 9 2025 · 12 2024 · 10 2023 · 8 2022 · 3 2021 · 8 2020 · 6 2018 · 4 2017 · 2 2016 · 2 2015 · 4 2013 · 179 dated

Dyne Therapeuticsdyne-tx.com in 𝕏NASDAQ: DYNAug 2020

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(President and Chief Executive Officer)in

Board seat Dirk Kersten· per SEC Form D

Co-investorsAtlas Venture MPM BioImpact Vida Ventures Wellington Management Hercules Capital, Inc.RA Capital

MapLight TherapeuticsNASDAQ: MPLTJul 2025 · $370M

MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease.

BiotechRedwood City, US

Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)James Lillie(Executive Officer)Jonathan Gillis(Executive Officer)inVishwas Setia(Executive Officer)inChristopher A. Kroeger(President, Chief Executive Officer and Director)

Board seat Nanna Lüneborg· per SEC Form D

Co-investorsAvego BioScience Capital Pivotal Life Sciences Novo Holdings

Damora TherapeuticsNASDAQ: DMRANov 2025 · $284.9M

Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.

BiotechCopenhagen, US

Garrett Winslow(Executive Officer)in Lori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)

Co-investorsAccess Biotechnology Viking Global Andreessen Horowitz BAM Elevate Bay City Capital Commodore Capital +8 more

Azafarosazafaros.comSeries A · Feb 2020 · $27M✓ verified

Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.

BiotechDeep TechHealthtechMedical DevicesLeiden, NL

Hans Aerts(Professor)Hermen Overkleeft(Professor)Stan van Boeckel(Professor)

Co-investorsBioGeneration Ventures BioMedPartners Jeito Capital Pictet Group Asahi Kasei Corporate Venture Capital Seroba Life Sciences

Beacontxbeacontx.com in 𝕏✓ verified

Beacon Therapeutics develops gene therapies for patients with serious diseases that lack or have limited treatment options, including investigational products like laru-zova for genetic conditions.

BiotechDigital HealthMedical Devices

Daniel Chung(Chief Medical Officer)in Lance Baldo(Chief Executive Officer)in Abraham Scaria(Chief Scientific Officer)in

Co-investorsAdvent Life Sciences Oxford Science Enterprises TCG Crossover

CatalYmcatalym.com inNov 2020✓ verified

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.

BiotechDeep TechHealthtechMunich, DE

Jörg Wischhusen(Scientific Co-founder)Scott Clarke(Chief Executive Officer)inPeter Garcia(Chief Financial Officer)Sujata Rao(Chief Medical Officer)in Stefan Ries(Chief Scientific Officer and Head of Munich Site)in Andrea Goddard(Chief Technical Officer)in

Co-investorsJeito Capital Bioqube Ventures Bayern Kapital BioGeneration Ventures Canaan Partners coparion +2 more

Citryllcitryll.com inSeries B · Dec 2024 · $90M✓ verified

Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones.

BiotechHealthtechMedical DevicesOss, NL

Renato Chirivi(Co-founder (former CSO))in

BoardPaul Peter Tak(Chair of the Board)

Co-investorsBioGeneration Ventures Pureos Bioventures Seventure Partners Johnson & Johnson Innovation – JJDC BOM Curie Capital +1 more

Elevaraelevara.com inOct 2025 · $70M✓ verified

Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.

BiotechHealthtechMedical DevicesLondon, GB

Emma Tinsley(Founder & former CEO (now Non-Executive Director))in Mai-Britt Zocca(CEO)in

Co-investorsMonograph Capital Partners Sofinnova Partners

Engrail Therapeuticsengrail.com inSeries B · Mar 2024 · $170M✓ verified

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsForesite Capital Longwood Fund Norwest Venture Partners Pivotal Life Sciences RiverVest Venture Partners Ysios Capital +4 more

Expeditiontxexpeditiontx.com✓ verified

Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology.

BiotechHealthtechMedical DevicesSan Francisco, US

Yi Larson(Founder and CEO)Geoff Gilmartin(Chief Medical Officer)Eric Hu(Chief Business Officer)

Co-investorsNovo Holdings Sofinnova Ventures Sanofi Ventures

Gate Biogatebio.comNov 2025✓ verified

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.

BiotechDeep TechMedical Devices

Jordi Mata-Fink(Chief Executive Officer, Co-Founder)in Raman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)in

Co-investorsVersant Ventures Andreessen Horowitz ARCH Venture Partners Felicis Ventures GV (Google Ventures)

Granite Biogranitebio.com inApr 2025 · $100M✓ verified

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

Patrick Loustau(President and Chief Executive Officer)in

Co-investorsNovartis Venture Fund Sanofi Ventures Versant Ventures

Kynexiskynexistx.com in 𝕏Series A · Nov 2023 · $61M✓ verified

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases.

BiotechDeep TechHealthtech

Robert Schwarcz(Scientific Co-founder)Carol Tamminga(Scientific Co-founder & Chair of the SAB)Christer Köhler(Founding Director)inKees Been(Chief Executive Officer)in Jens Wendland(Chief Medical Officer)inNeil Swami(Chief Business Officer)

Co-investorsYsios Capital Novartis Venture Fund Sunstone Capital

Mestagmestagtherapeutics.com in 𝕏Mar 2026 · $40M✓ verified

Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.

AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB

Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)Lindsey Rolfe(Chief Medical Officer)in

Co-investorsGV (Google Ventures)SV Health Investors Johnson & Johnson Innovation – JJDC Northpond Ventures JJDC

Omeicos Therapeuticsomeicos.com in 𝕏Series C · Nov 2018 · $19M✓ verified

OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases.

BiotechHealthtechBerlin, DE

Robert Fischer(CEO/CSO & Co-Founder)in Karen Uhlmann(Vice President Operations & IP, Co-Founder)inWolf-Hagen Schunck(Co-Founder)John R. Falck(Co-Founder)

Co-investorsRemiges Ventures, Inc.Vesalius Biocapital Partners

Pheontxpheontx.com in✓ verified

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

BiotechHealthtechMedical Devices

Co-investorsAtlas Venture Biotechnology Value Fund Lightspeed Venture Partners Research Corporation Technologies TCG Crossover

Purespringpurespringtx.com in 𝕏Oct 2024✓ verified

Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.

BiotechDigital HealthHealthtechMedical Devices

Moin Saleem(Co-founder & Chief Scientific Advisor)in

Co-investorsSofinnova Partners Gilde Healthcare Advent Life Sciences British Patient Capital

Solstice Oncologysolsticeoncology.comMar 2026✓ verified

Solstice Oncology is a clinical-stage immuno-oncology company developing porustobart, a second-generation engineered CTLA-4 antibody given with anti–PD-1 therapy in the neoadjuvant (pre-surgery) setting to treat early-stage cancers.

BiotechHealthtechBoston, US

David Feltquate(Chief Medical Officer)inMaiken Keson-Brookes(Chief Operating Officer & General Counsel)CAROLINE LOEW(Executive Officer, Director, Promoter)Caroline J. Loew(President & Chief Executive Officer)

Board ANDREW LEVIN(Director)JULIE GRANT(Director)in

Co-investorsRA Capital Canaan Partners

SynOx Therapeutics Ltdsynoxtherapeutics.com in 𝕏Series A · Nov 2020 · $44M✓ verified

SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.

BiotechHealthtechMedical Devices

Ray Barlow(Chief Executive Officer)in

Co-investorsHealthCap Bioqube Ventures Gimv Medicxi Red Tree Venture

ロゴマーク：AIRNAairna.com inSeries B · Sep 2021 · $160M✓ verified

AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.

AI & Machine LearningBiotechDeep TechHealthtechStanford, US

Thorsten Stafforst(Chairman of the Board of Directors)in Kris Elverum in Todd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in

BoardRodger Novak(Chair)in

Co-investors+ND Capital ARCH Venture Partners Venrock Fast Track Initiative Lifelink Nextech Invest +3 more

Capstan Therapeuticscapstantx.com 𝕏Series B · Nov 2021 · $180M

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

BiotechHealthtechMedical DevicesSan Diego, US

Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)in Ramin Farzaneh-Far(Executive Officer)inJustin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)

Board seat Nanna Lüneborg· per SEC Form D

Co-investorsFinchley Healthcare Ventures Pfizer Venture Investments RA Capital Sofinnova Ventures Vida Ventures Alexandria

Exosome Diagnostics inSeries A · Jun 2015 · $20M

BiotechHealthtechCambridge, US

James McCullough(Executive Officer, Director)William Kelly(Chief Financial Officer and Secretary of Issuer)Thomas McLain(Chief Executive Officer and Director of Issuer)Sara Barrington(Executive Officer)

BoardJoseph Boystak(Director)in

Board seat Geert-Jan Mulder· per SEC Form D

Co-investorsArcus Ventures NGN Capital

Milestone Pharmaceuticalsmilestonepharma.com in 𝕏Series C · Jul 2017 · $55M

Milestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.

BiotechDigital HealthHealthtechMedical DevicesMontreal, US

Ela Borenstein(Director)Francis Plat(Executive Officer)Yves Rosconi(Director)Scott Weiner(Director)Martin Maguire(Executive Officer)Philippe Douville(Executive Officer, Director)

Board seat Marco Boorsma· per SEC Form D

Co-investorsPappas Capital Amplitude Venture Capital Domain Associates RTW Investments L.P.

AAVantgarde Bioaavantgarde.comSeries A · Jun 2023 · $65M

Co-investorsNeva Sgr.Sofinnova Partners XGEN Venture Atlas Venture Longwood Fund

Abiomedabiomed.com

Abiomed develops Impella heart pumps, minimally-invasive cardiovascular devices used to treat high-risk PCI, cardiogenic shock, and right heart failure.

HealthtechMedical Devices

David Lederman(Founder)

Acadia Pharmaceuticalsacadia.com in 𝕏

Acadia is a biopharmaceutical company developing therapies for underserved neurological disorders and rare diseases.

BiotechHealthtech

Co-investorsNew Enterprise Associates (NEA)

Agendiaagendia.com in 𝕏Aug 2007 · $34M

Agendia develops genomic technology and diagnostic tests for breast cancer patients.

AI & Machine LearningBiotechDigital HealthMedical DevicesIrvine, US

Laura van 't Veer(Co-founder)in René Bernards(Co-founder)inProf. Laura van 't Veer, PhD(Chief Research Officer, Co-founder)Prof. Dr. René Bernards, PhD(Co-Founder and Scientific Advisor)Mark R. Straley(CEO)in

Co-investorsKorys Gilde Healthcare

Aiolos Bioaiolosbio.com in 𝕏

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsBain Capital Life Sciences RA Capital Sofinnova Ventures Atlas Venture

Allecra Therapeutics GmbHallecra.comSeries A · Apr 2013 · $20M

Antibiotic developer, maker of cefepime/enmetazobactam (EXBLIFEP).

Co-investorsAndera Partners BioMedPartners Delos Capital EMBL Ventures Xeraya Capital

Altesa BioSciencesaltesabio.comFeb 2026 · $75M

Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma.

BiotechHealthtechCollege Park, US

John Clerici(Executive Officer)inAndrew Drechsler(Executive Officer)Brett Giroir(Executive Officer, Director)

Board Nicholas Williams(Director)Moncef Slaoui(Director)Jon Edwards(Director)in

Co-investorsGRA Venture Medicxi Pitango Sanofi Ventures

AM Pharmaam-pharma.com inSeries C · Aug 2007 · $3M

AM-Pharma develops ilofotase alfa, a recombinant alkaline phosphatase enzyme therapy, and is studying it as a treatment for adults with hypophosphatasia (HPP), a rare inherited metabolic bone disease.

BiotechHealthtech

Co-investorsAndera Partners Kurma Partners Ysios Capital

Amphista Therapeuticsamphista.com in 𝕏

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)in Giles Brown(Executive VP Drug Discovery)in

Co-investorsAdvent Life Sciences Novartis Venture Fund SV Health Investors Dementia Discovery Fund European Investment Fund Gilde Healthcare +2 more

Anaveonanaveon.com inSeries B · Dec 2021 · $120M

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.

BiotechBasel, CH

Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in

Co-investorsNovartis Venture Fund Pfizer Venture Investments Pontifax Venture Capital

Anetaaneta.companyMay 2023

Aneta operates an email-based AI research service that runs 15 specialized agents across academic, market, technical, and legal sources for days to produce long, citation-backed research reports.

AI & Machine LearningEnterprise SoftwareSaaS

Co-investorsPebblebed Andera Partners BGV Fountain Healthcare Partners HTGF PMV +2 more

arGEN-Xargenx.com

The company develops therapies for people with severe autoimmune diseases.

BiotechHealthtechMedical Devices

Co-investorsAvoro Capital Advisors BioGeneration Ventures HBM Healthcare Investments MPM BioImpact PMV Seventure Partners +2 more

Bluebird Biobluebirdbio.com 𝕏Sep 2021Acquired

Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.

BiotechLongevityMedical DevicesCambridge, US

David Meek(Chief Executive Officer)inBrian Riley(President & Chief Technical Officer)in Joanne Lager(Chief Medical Officer)in Wendy DiCicco(Chief Financial Officer)in Adrian Chaisson(Chief of Staff)inJason Cole(Executive Officer)

Co-investorsARCH Venture Partners Easton Capital RA Capital Sanofi Ventures Think+ Ventures Management, Llc Wakestream Ventures +1 more

Braveheartbraveheart.bio inSeries A · Nov 2025 · $190M

Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.

BiotechDigital HealthHealthtechMedical Devices

Travis Murdoch, M.D.(Chief Executive Officer and Board Director)in

Co-investorsAndreessen Horowitz Frazier Life Sciences OrbiMed

Calluna Pharmacallunapharma.com inSeries A · Jan 2024 · $81M

Completed patient enrollment in its Phase 2 AURORA trial.

Co-investorsP53 Invest Sarsia Management AS Investinor

CellCentriccellcentric.com in 𝕏Series C · May 2025 · $120M

CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers.

BiotechHealthtechMedical Devices

Azim Surani(Co-founder)

Co-investorsAvego BioScience Capital Future Planet Capital HBM Healthcare Investments HBM Partners RA Capital Sofinnova Partners +3 more

Complement Therapeuticscomplementtx.comSeed · Apr 2023 · $6M

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.

BiotechDigital HealthHealthtechMedical DevicesMunich, DE

Rafiq Hasan(CEO and Managing Director)in Muhammad Ali Memon(Chief Medical Officer)in

Co-investorsBioGeneration Ventures Cambridge Innovation Capital Gimv Hadean Ventures Seroba Life Sciences BGV +2 more

Coultreoncoultreon.com inApr 2026 · $125M

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine LearningBiotech

Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)in Marie De Vulder(Chief Legal Officer Co-founder)in Guy Peeters(Chief Financial Officer Co-founder)in John-Paul Gallivan(Head of Development Co-founder)in Fabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in

Co-investorsFinchley Healthcare Ventures Longwood Fund Luma Group Sofinnova Ventures BAM Elevate Novo Holdings +2 more

Curetiscuretis.comSeries A · Oct 2011 · $13M

Curetis develops molecular diagnostic systems for detecting pathogens and antimicrobial resistance markers in severe infections.

BiotechHealthtechMedical Devices

Enterprise Therapeuticsenterprisetherapeutics.com in 𝕏Series B · Apr 2018 · $41M

Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD.

BiotechHealthtechBrighton, GB

John Ford(Co-founder)in Martin Gosling(Founder)in

Co-investorsEpidarex Capital Novartis Venture Fund Versant Ventures IP Group Panakes Partners

F2Gf2g.comAug 2022 · $70M

F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsAdvent Life Sciences Aisling Capital AMR Action Fund Astellas Venture Management LLC Brace Pharma Sofinnova Partners +4 more

Gategate.io in 𝕏

Gate.io is a cryptocurrency exchange platform offering perpetual futures contracts, options, CFDs, spot trading, and tokenized stocks.

AI & Machine LearningCrypto & Web3Fintech

Co-investorsTokoin

Genominesgenomines.com in

Genomines uses biological systems to extract battery-grade nickel from low-grade soils, producing critical metals at lower cost and environmental impact than traditional mining.

BiotechCleantechEnergyNew MaterialsParis, FR

Fabien Koutchekian(Founder)in Dali Rashid(Founder)inDr. Dali Rashid(Founder)

Co-investorsCarbon DeepTech & Climate Fonds Entrepreneur First HEC Paris Incubator Lowercarbon Capital STATION F +7 more

Inflazomeinflazome.comSeries B · Nov 2018 · $46M

Co-investorsFountain Healthcare Partners Longitude Capital

Inthera Bioscienceintherabio.comSeed · Dec 2015 · $4M

Inthera Bioscience AG is a biotech company with expertise spanning target discovery, drug discovery, medicinal chemistry, preclinical and toxicology work, and early clinical development.

BiotechDeep Tech

Mark Krul(Board of Directors)inKarl Rothweiler(Board of Directors)Martin Bonde(Board of Directors)

Co-investorsM Ventures

Inversagoinversago.comSeries B · Oct 2022 · $35Macquired by Novo Nordisk

Portfolio company acquired by Novo Nordisk for $1.1B USD.

Co-investorsAmorChem Genesys Capital JDRF T1D Fund New Enterprise Associates (NEA)Tarnagulla Ventures adMare BioInnovations +2 more

LoQus23loqus23.com inOct 2024

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

David Reynolds(Co-founder & CEO)in Caroline Benn(Co-founder & CSO)in

Co-investorsDementia Discovery Fund Novartis Venture Fund SV Health Investors

Maplightrxmaplightrx.com in

MapLight develops neurological and neuropsychiatric drug therapies using a discovery platform that identifies neural circuits linked to disease for targeted treatment of conditions like schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder.

AI & Machine LearningBiotechHealthtechMedical Devices

Christopher Kroeger, M.D.(Chief Executive Officer, Founder, Board Member)Karl Deisseroth, M.D., Ph.D.(Founder, Scientific Advisory Board)Robert Malenka, M.D., Ph.D.(Founder, Board Member, Scientific Advisory Board)Christopher Kroeger(Founder)Karl Deisseroth(Founder)Karoly Nikolich(Founder)

Co-investorsAvego BioScience Capital Pivotal Life Sciences

Mariana Oncologymarianaoncology.com in 𝕏Series B · Sep 2023 · $175M

Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.

BiotechHealthtechMedical Devices

Co-investorsAccess Biotechnology Atlas Venture Nextech Invest Access Industries RA Capital

Mitralignmitralign.comMay 2012 · $35M

HealthtechTewksbury, US

Lisa Mastromattei(Executive Officer)Lisa Wipperman Heine(Executive Officer)Sophia Wong(Executive Officer)Richard P. Geoffrion(Executive Officer, Director)

BoardMartien Van Osch(Director)Daniel Cole(Director)

Co-investors415 Capital Qiming Venture Partners Saints Capital Xeraya Capital Oxford Bioscience Partners

Mosannamosanna.com

Mosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep.

BiotechDigital HealthHealthtechMedical Devices

Barbara(Regulatory Affairs & Quality Assurance leadership)Kevin(Pharmaceutical Development leadership)Pranav(Head of Finance & Operations)Ben(Executive / Board)

BoardDavid White(Sleep Medicine Advisor)

Co-investorsBroadview Ventures Norwest Venture Partners Pivotal Life Sciences Supermoon Capital HTGF Inkef

MSTmst-sys.comMar 2026 · $40M

Modern Systems Talk (MST) publishes content and insights on technology topics including system architecture, cloud computing, automation, AI, cybersecurity, and digital transformation.

Media & Entertainment

Co-investorsAgate Medical Investments LP SCP Vitalife Partners GV (Google Ventures)Northpond Ventures SV Health Investors

Nerre Therapeuticsnerretherapeutics.comSeries B · Jan 2017 · $29M

Co-investorsAdvent Life Sciences Fountain Healthcare Partners OrbiMed Columbus Venture Partners Redwood Ventures

NewAmsterdam Pharmanewamsterdampharma.com in 𝕏Series A · Jan 2021 · $190M

NewAmsterdam Pharma develops innovative therapies for cardiovascular disease and lipid-related conditions.

BiotechHealthtechMedical Devices

Co-investorsBain Capital Life Sciences BioGeneration Ventures EQT Life Sciences Frazier Life Sciences

Noema Pharmanoemapharma.com inSeries B · Nov 2025 · $110M

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

Ilise Lombardo(Chief Executive Officer)in Volker Knappertz(Executive Vice President of Research & Development)in Michael Samar(Chief Financial Officer)in Rob Lasser(Chief Medical Officer)in

Co-investorsBioMedPartners Jeito Capital Roche Venture Fund Sofinnova Partners EQT EQT Life Sciences +2 more

Northsea Therapeuticsnorthseatherapeutics.com inSeries B · Jan 2020 · $40M

NorthSea Therapeutics is a clinical-stage biopharmaceutical company developing oral fatty acid-derived therapies for liver and metabolic diseases, including intestinal failure-associated liver disease (IFALD), severe hypertriglyceridemia, and MASH.

BiotechDigital HealthHealthtech

Co-investorsNew Science Ventures venBio Partners Ysios Capital BGV Novo Holdings BioGeneration Ventures +1 more

Novameatnovameat.com inSep 2024

NovaMeat develops plant-based protein food products, positioning them as part of a new culinary tradition.

FoodTech

Giuseppe Scionti(Founder)in

Co-investorsAurum Venture Partners Carbon Joyance Partners Sofinnova Partners Unovis Asset Management VU Venture Partners +1 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Gyroscope Therapeutics LtdMemento Medicines Navigator MedicinesAcorda TherapeuticsAmakemBeacon TherapeuticsBicycle TherapeuticsBioCerosBioInventcAMPfield TherapeuticsCellnovoCircuLiteCorsera HealthDezima PharmaeedenExpedition TherapeuticsGalapagosGotham TherapeuticsInsmedKaNDy TherapeuticsMarea TherapeuticsNightbalanceNovoGIOxularOxyrane UKPanGeneticsPheon TherapeuticsPneumRxProfibrixRealeveSantaris PharmaSlate Medicines IncStaten BiotechnologyVectivBioVectorYVersanis Bio

Exits · 6

3 IPOs · 3 acquisitions · showing 5

Dyne TherapeuticsNASDAQ: DYNMapLight TherapeuticsNASDAQ: MPLTDamora TherapeuticsNASDAQ: DMRAInversagoacq. by Novo NordiskPrexton Therapeuticsacq. by Lundbeck

Portfolio news

latest coverage across their companies

Roundup: Orbis Enters $1.4 Billion Partnership with Novo, Dualitas Therapeutics Enters Research collaboration with Roche, Aethlon Medical Merges with North Immunology | PharmExec

Orbis Medicines · pharmexec.com · Sep 17, 2026

Solstice Oncology Launches with $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

Solstice Oncology · globenewswire.com · Sep 9, 2026

AfterQuery Raises Funding at $3.2B Valuation, 10x Growth in Five Months Since Series A | Gate News

Gate · gate.com · Sep 2, 2026

RQ Bio Raises £85.5M in Series A Funding

RQ Bio · finsmes.com · Jun 24, 2026

CellCentric Raises $220M in Series D Funding

CellCentric · finsmes.com · May 6, 2026

Coultreon Biopharma Raises $125 Million in Series A Financing to Advance Immunology Pipeline

Coultreon · coultreon.com · Apr 28, 2026

Mestag Therapeutics Raises $40M in Financing

Mestag · finsmes.com · Mar 17, 2026

Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases

Altesa BioSciences · prnewswire.com · Feb 19, 2026

Fund performance · per public LP disclosures · 5

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Forbion BioEconomy Fund I Co?peratief U.A.LPs: California Public Employees' Retirement System	2024	—	—	0.90x	0.00x
Forbion Growth Opportunities Fund III Co?peratief U.A.LPs: California Public Employees' Retirement System	2024	—	—	0.65x	0.07x
Forbion Ventures Fund VII Co?peratief U.A.LPs: California Public Employees' Retirement System	2024	—	—	0.85x	0.01x
Forbion Growth Opportunities Fund II Cooperatief U.A.LPs: California Public Employees' Retirement System	2023	—	—	1.64x	1.01x
Forbion Ventures Fund VI Cooperatief U.A.LPs: California Public Employees' Retirement System	2023	—	—	1.34x	0.34x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

How many investments has Forbion made?: Forbion has 121 tracked investments, 6 of which have exited, including 23 dated in the last 24 months.
What stage does Forbion invest at?: Forbion invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does Forbion focus on?: Forbion focuses on AgTech, Biotech, Cleantech, Climate Tech, FoodTech, Healthtech, Impact & Social Good, Medical Devices, New Materials.
Where is Forbion located?: Forbion is headquartered in Naarden, NL.
Does Forbion lead rounds?: Forbion has led 10 of the 25 rounds where its role is on record.
Who does Forbion co-invest with?: Forbion most often shares deals with BioGeneration Ventures, BioMedPartners, DeepTech & Climate Fonds, among 13 tracked co-investors.

Media · Podcasts & interviews

featuring the team

BIO-Europe® 2015: Interview with Sander Slootweg, Forbion Capital Partners

EBD Group · Sander Slootweg

Forbion Portfolio Company Spotlight Series | Episode 2: AAVantgarde

Forbion

Forbion Portfolio Company Spotlight Series | Episode 1: VectorY

Forbion

Message by Olivér Várhelyi on the occasion of the European Life Sciences Coalition

Forbion

Forbion 2nd Annual Excellence Roundtable: The future of innovation in rare diseases

Forbion

From Bench to Boardroom: The 2nd Annual Cambridge–Forbion Roundtable

Forbion

Images

Co-investors · 41

RA Capital

RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.

Both backed · 14

Damora Therapeutics Dyne Therapeutics Aiolos Bio Bluebird Bio Capstan Therapeutics CellCentric Mariana Oncology Memento Medicines Navigator Medicines Oncology Sidera Bio Solstice Oncology Sparrow Pharma Verdiva Bio

Novartis Venture Fund

The Novartis Venture Fund invests in innovative life science companies, primarily in biotechnology and biopharmaceuticals, at various stages of development across North America and Europe.

Both backed · 11

Amphista Therapeutics Anaveon CatalYm Citryll Enterprise Therapeutics F2G Granite Bio Kynexis LoQus23 Protego Protego Biopharma

$5M – $25M

BioGeneration Ventures

BioGeneration Ventures is a European venture capital firm investing in early-stage biotech, medtech and life sciences companies developing novel therapeutics and medical technologies.

Both backed · 9

arGEN-X Azafaros CatalYm Citryll Complement Therapeutics NewAmsterdam Pharma Northsea Therapeutics Tessellate BIOVectorY

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 7

CellCentric Elevara F2G Noema Pharma Novameat PurespringAAVantgarde Bio

$540K – $27M

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

Both backed · 7

Aiolos Bio Capstan Therapeutics Coultreon Expeditiontx Northsea Therapeutics PromediorGyroscope Therapeutics Ltd

$100K – $15M

Advent Life Sciences

Advent Life Sciences is a trans-Atlantic venture capital firm investing in early and mid-stage life sciences companies across the UK, Europe and the USA.

Both backed · 7

Amphista Therapeutics Beacontx F2G Purespring UniqureBeacon TherapeuticsNerre Therapeutics

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 6

Dyne Therapeutics Aiolos Bio Mariana Oncology Pheontx RectifypharmaAAVantgarde Bio

$500K – $1M

OrbiMed

OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 6

Damora Therapeutics Braveheart Rampart Bioscience Sparrow Pharma Verdiva BioNerre Therapeutics

$1M – $75M

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies aligned with Sanofi's mission of advancing human health.

Both backed · 5

Altesa BioSciences Bluebird Bio Expeditiontx Granite Bio Memento Medicines

$5M

Ysios Capital

Ysios Capital is a life sciences venture investor that finances innovative biotech companies developing novel therapies for high unmet medical needs, primarily across Europe and the United States.

Both backed · 5

AM Pharma Engrail Therapeutics Kynexis Northsea Therapeutics Prexton Therapeutics

$5.4M – $21.6M

Inkef

Inkef Capital is an early-stage, hands-on investor that partners with founders to build companies with a long-term strategic vision.

Both backed · 5

Mosanna ViCentraNightbalancePRECIRIX NVProfibrix

Longwood Fund

Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.

Both backed · 5

Coultreon Engrail Therapeutics Progentos Therapeutics RectifypharmaAAVantgarde Bio

▶29 more co-investors

ARCH Venture Partners EQT Life Sciences Pivotal Life Sciences Red Tree Venture New Enterprise Associates (NEA)Versant Ventures Andera Partners Seventure Partners Seroba Life Sciences F-Prime Capital HTGF Pfizer Venture Investments Nextech Invest RiverVest Venture Partners RTW Investments L.P.US Venture Partners General Atlantic Cambridge Innovation Capital Domain Associates Third Rock Ventures Kurma Partners Access Industries Alta Partners Arcus Ventures Founders Fund Polaris Partners Xtripe Angels 5AM Ventures 4see Ventures

Firms observed investing alongside Forbion, from public investor directories. Shared companies are the overlap with Forbion's recorded portfolio.

Similar investors

Sofinnova Partners

$540K – $27M

Starquest Capital

Starquest Capital is a Paris-based, climate-focused investment firm (part of the Montefiore group) financing high-tech, low-carbon innovation through several thematic funds spanning biodiversity, climate adaptation, and emissions reduction.

$550K – $22M

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Oost NL

Oost NL is a regional development agency that supports and connects innovative entrepreneurs in the Dutch provinces of Gelderland and Overijssel, helping accelerate technological innovation through capital, network, and knowledge.

$108K – $5.4M